Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Efficacy and Pharmacokinetics of XKDCT023 in Adult Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma

NCT05269914 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

NCT NCT05269914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05269914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Efficacy and Pharmacokinetics of XKDCT023 in Adult Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Not applicable
Overall status
Unknown status
Start date
April 30, 2022
Completion date
June 30, 2023
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma